Published in Neth J Med on April 01, 2004
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest (2008) 1.59
Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging (2009) 1.04
Mice with alopecia, osteoporosis, and systemic amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase. PLoS Genet (2010) 1.02
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One (2012) 0.96
Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol (2014) 0.86
Liquid nitrogen cryotherapy for surface eye disease (an AOS thesis). Trans Am Ophthalmol Soc (2008) 0.85
Diagnosis of amyloidosis and differentiation from chronic, idiopathic enterocolitis in rhesus (Macaca mulatta) and pig-tailed (M. nemestrina) macaques. Comp Med (2013) 0.79
New device technologies for subcutaneous fat biopsy. Amyloid (2012) 0.78
Cellular mechanism of fibril formation from serum amyloid A1 protein. EMBO Rep (2017) 0.76
Systemic amyloidosis: are we moving ahead? Neth J Med (2004) 0.76
A rare cause of lower GI bleeding. BMJ Case Rep (2012) 0.75
Generating local amyloidosis in mice by the subcutaneous injection of human insulin amyloid fibrils. Exp Ther Med (2014) 0.75
Ectropion and Conjunctival Mass in a Patient with Primary Bilateral Conjunctival Amyloidosis. Case Rep Ophthalmol Med (2016) 0.75
Endoscopic Findings of Small-Bowel Lesions in Familial Amyloid Polyneuropathy: A Case Report. Medicine (Baltimore) (2016) 0.75
Primary systemic amyloidosis as a real diagnostic challenge - case study. Cent Eur J Immunol (2014) 0.75
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis (1990) 5.49
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol (1994) 3.50
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol (1996) 3.36
Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum (1992) 3.05
No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol (2001) 2.31
Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol (1992) 2.29
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis (1992) 2.26
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. Arthritis Rheum (1990) 2.14
IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol (1995) 1.76
Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum (1988) 1.61
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev (2004) 1.60
Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol (2002) 1.54
Increased circulating cytokine receptors and ex vivo interleukin-1 receptor antagonist and interleukin-1beta production but decreased tumour necrosis factor-alpha production after a 5-km run. Eur J Clin Invest (1998) 1.50
Sentinel node detection in patients with breast cancer: low-energy all-purpose collimator or medium-energy collimator? Clin Nucl Med (2004) 1.47
No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis (2000) 1.40
Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol (1993) 1.39
[Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients]. Ned Tijdschr Geneeskd (2005) 1.39
[AL-amyloidosis and its treatment by eliminating the precursor protein]. Ned Tijdschr Geneeskd (2007) 1.39
[Current criteria of the American Rheumatism Association for the classification of rheumatoid arthritis]. Ned Tijdschr Geneeskd (1990) 1.39
Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. Amyloid (2001) 1.38
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta (1991) 1.38
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol (1997) 1.34
The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol (1993) 1.33
Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol (1998) 1.33
Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem (1994) 1.31
Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol (1997) 1.27
Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin Rheumatol (1994) 1.20
The potassium permanganate method. A reliable method for differentiating amyloid AA from other forms of amyloid in routine laboratory practice. Am J Pathol (1979) 1.15
C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol (1990) 1.14
Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis (1990) 1.13
[Efficient and improved diagnosis of osteoporosis by simultaneous bone density measurement and spinal morphometry]. Ned Tijdschr Geneeskd (2008) 1.12
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer (2005) 1.12
Adult onset Still's disease in the elderly: a report of two cases. J Rheumatol (1985) 1.10
Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol (1991) 1.10
Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging (2008) 1.08
Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J (1992) 1.07
Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol (1992) 1.06
Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis (2004) 1.03
Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med (1990) 1.01
Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy (2008) 1.00
Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis (1995) 1.00
Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol (2010) 0.99
Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol (2000) 0.99
Quantitation of IgM, IgA and IgG rheumatoid factors by ELISA in rheumatoid arthritis and other rheumatic disorders. Scand J Rheumatol Suppl (1988) 0.98
Development and validation of a patient-tailored dose regime in myocardial perfusion imaging using CZT-SPECT. J Nucl Cardiol (2014) 0.97
Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol (2004) 0.96
Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) (1999) 0.95
Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis (1995) 0.94
CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis. Hum Antibodies (2011) 0.93
High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE). Lupus (2013) 0.92
Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol (2003) 0.92
Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol (1994) 0.91
Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg (2006) 0.91
Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis (2002) 0.90
Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford) (2008) 0.89
A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis (1999) 0.89
Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg (2007) 0.89
Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides. Clin Exp Rheumatol (2004) 0.89
Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging (2005) 0.88
Functional ability, social support, and depression in rheumatoid arthritis. Qual Life Res (2004) 0.87
Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med (1998) 0.87
Influence of a ceiling effect on the assessment of radiographic progression in rheumatoid arthritis during the first 6 years of disease. J Rheumatol (1999) 0.86
PET-CT: a matter of opinion? Eur J Nucl Med Mol Imaging (2003) 0.85
Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res (1996) 0.85
Weather conditions and complaints in fibromyalgia. J Rheumatol (1993) 0.85
Quantitation of antibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease. Clin Exp Immunol (1985) 0.84
Soft-tissue uptake of 99mTc-diphosphonate in systemic AL amyloidosis. Eur J Nucl Med (1984) 0.84
Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol (2009) 0.84
Where has secondary amyloid gone? Ann Rheum Dis (2000) 0.84
Classification of amyloidosis: immunohistochemistry versus the potassium permanganate method in differentiating AA from AL amyloidosis. Appl Pathol (1985) 0.83
Immunoglobulin allotypes are not involved in systemic amyloidosis. J Rheumatol (1985) 0.83
Condensing osteitis of the clavicle: magnetic resonance imaging as an adjunct method for differential diagnosis. Ann Rheum Dis (1992) 0.83
Comparison of 99mTc-sestamibi-18F-fluorodeoxyglucose dual isotope simultaneous acquisition and rest-stress 99mTc-sestamibi single photon emission computed tomography for the assessment of myocardial viability. Nucl Med Commun (2003) 0.82
Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J Intern Med (2004) 0.82
Pitfalls in the sentinel lymph node procedure in vulvar cancer. Gynecol Oncol (2004) 0.82
Clinical value of gallium-67 scintigraphy in assessment of disease activity in Wegener's granulomatosis. Ann Rheum Dis (2003) 0.82
Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) (2000) 0.82
Fluctuations in anti-nRNP levels in patients with mixed connective tissue disease are related to disease activity as part of a polyclonal B cell response. Ann Rheum Dis (1986) 0.81
Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? Clin Exp Immunol (2014) 0.81
Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid (2005) 0.81
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. Br J Pharmacol (2012) 0.81
Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol (2005) 0.80
Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor. Scand J Gastroenterol (2004) 0.80
In vivo 31P magnetic resonance spectroscopy (MRS) of tender points in patients with primary fibromyalgia syndrome. Rheumatol Int (1991) 0.80
Zero coronary calcium in the presence of three-vessel and left main coronary artery disease in a Hodgkin lymphoma survivor. Neth Heart J (2015) 0.80
Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand J Gastroenterol (2001) 0.79
Elevated D8/17 expression on B lymphocytes, a marker of rheumatic fever, measured with flow cytometry in tic disorder patients. Am J Psychiatry (2001) 0.79
Dimethylsulphoxide in amyloidosis. Lancet (1979) 0.79
Specific glycosylation of alpha(1)-acid glycoprotein characterises patients with familial Mediterranean fever and obligatory carriers of MEFV. Ann Rheum Dis (2001) 0.79